LeMaitre Vascular, Inc.

Equities

LMAT

US5255582018

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 10:30:00 03/07/2024 pm IST			5-day change	1st Jan Change
81.3 ^USD	+0.14%		-0.72%	+43.23%

01/07	LeMaitre Vascular, Inc.(NasdaqGM:LMAT) dropped from Russell Microcap Index	CI
01/07	LeMaitre Vascular, Inc.(NasdaqGM:LMAT) dropped from Russell Microcap Growth Index	CI

Lemaitre Vascular, Inc. Provides Earnings Guidance for the Second Quarter of 2021

April 30, 2021 at 01:36 am IST

LeMaitre Vascular, Inc. announced earnings guidance for the second quarter of 2021. For the quarter, the company expects operating Income of $8.0 million - $10.0 million, Earnings Per Share of $0.28 - $0.36 and sales of $37.0 million - $40.0 million.

Latest news about LeMaitre Vascular, Inc.

LeMaitre Vascular, Inc.(NasdaqGM:LMAT) dropped from Russell Microcap Index	01/07	CI
LeMaitre Vascular, Inc.(NasdaqGM:LMAT) dropped from Russell Microcap Growth Index	01/07	CI
LeMaitre Vascular, Inc.(NasdaqGM:LMAT) dropped from Russell 3000E Growth Index	01/07	CI
Lemaitre Vascular, Inc. Announces Resignation of Lawrence J. Jasinski as A Director	04/06	CI
Roth MKM Upgrades LeMaitre Vascular to Buy Rating With $100 Price Target	31/05	MT
Tranche Update on LeMaitre Vascular, Inc.'s Equity Buyback Plan announced on February 27, 2024.	10/05	CI
Tranche Update on LeMaitre Vascular, Inc.'s Equity Buyback Plan announced on February 23, 2023.	10/05	CI
Lemaitre Vascular Insider Sold Shares Worth $9,314,501, According to a Recent SEC Filing	09/05	MT
Lemaitre Vascular Insider Sold Shares Worth $379,991, According to a Recent SEC Filing	09/05	MT
Barrington Boosts Price Target on LeMaitre Vascular to $79 From $69, Keeps Outperform Rating	03/05	MT
Transcript : LeMaitre Vascular, Inc., Q1 2024 Earnings Call, May 02, 2024	03/05
Earnings Flash (LMAT) LEMAITRE VASCULAR Posts Q1 Revenue $53.5M, vs. Street Est of $51.5M	03/05	MT
(LMAT) LEMAITRE VASCULAR Sees Fiscal Year 2024 EPS $1.79	03/05	MT
(LMAT) LEMAITRE VASCULAR Expects Q2 EPS $0.47	03/05	MT
(LMAT) LEMAITRE VASCULAR Forecasts Q2 Revenue $50.1M	03/05	MT
LeMaitre Vascular, Inc. Provides Earnings Guidance for the Second Quarter and Full Year 2024	03/05	CI
LeMaitre Vascular, Inc. Approves Quarterly Cash Dividend, Payable on May 30, 2024	03/05	CI
LeMaitre Vascular, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	03/05	CI
North American Morning Briefing : Investors Brace -2-	29/04	DJ
Stifel Upgrades LeMaitre Vascular to Buy From Hold, Adjusts Price Target to $75 From $59	26/04	MT
Lemaitre Vascular Insider Sold Shares Worth $309,684, According to a Recent SEC Filing	13/03	MT
Lemaitre Vascular Insider Sold Shares Worth $344,925, According to a Recent SEC Filing	08/03	MT
Lemaitre Vascular Insider Sold Shares Worth $517,500, According to a Recent SEC Filing	08/03	MT
Tranche Update on LeMaitre Vascular, Inc.'s Equity Buyback Plan announced on February 23, 2023.	01/03	CI
Health Care Drops After Mixed Earnings -- Health Care Roundup	29/02	DJ

Chart LeMaitre Vascular, Inc.

Duration

Period

More charts

Company Profile

LeMaitre Vascular, Inc. is a provider of devices, implants, and services for the treatment of peripheral vascular disease. The Company develops, manufactures, and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. Its portfolio of product lines is primarily used to treat vascular disease, of which most are used in open vascular surgery and dialysis access. It also offers human vascular and cardiac tissue cryopreservation services. Its principal product lines include anastomotic clips, biologic vascular and dialysis grafts, biologic vascular and cardiac patches, carotid shunts, embolectomy catheters, occlusion catheters, radiopaque marking tape, synthetic vascular and dialysis grafts, and valvulotomes. The Companyâs principal biologic offerings include vascular and cardiac patches as well as vascular and dialysis grafts. The Company sells its products and services primarily through a direct sales force.

Sector

Advanced Medical Equipment & Technology

Calendar

25/07/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for LeMaitre Vascular, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

81.3 USD

Average target price

81.25 USD

Spread / Average Target

-0.06%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
LEMAITRE VASCULAR, INC.	+43.23%	182.49Cr
THERMO FISHER SCIENTIFIC	+0.91%	20TCr
DANAHER CORPORATION	+3.74%	18TCr
INTUITIVE SURGICAL, INC.	+28.89%	15TCr
BOSTON SCIENTIFIC CORPORATION	+31.66%	11TCr
SIEMENS HEALTHINEERS AG	+1.33%	6.42TCr
EDWARDS LIFESCIENCES CORPORATION	+19.45%	5.49TCr
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-3.44%	4.67TCr
AGILENT TECHNOLOGIES, INC.	-9.28%	3.68TCr
GE HEALTHCARE TECHNOLOGIES INC.	-0.10%	3.53TCr

Other Advanced Medical Equipment & Technology